{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.77","upperLimit":"3.71","value":"1.85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"The distribution of progression-free survival times will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"MEDIAN","populationDescription":"All participants were evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Every 3 months from registration until progressive disease (PD), assessed up to 2 years after registration","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"months"}